Singular Genomics Systems Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Singular Genomics Systems wird ein Gewinn- und Umsatzwachstum von 2.8% bzw. 79.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 16.4% pro Jahr wachsen soll.

Wichtige Informationen

2.8%

Wachstumsrate der Gewinne

16.4%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	16.7%
Wachstumsrate der Einnahmen	79.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Singular Genomics cut to Neutral at UBS on delays for sequencer shipments

Aug 17

Singular Genomics Systems GAAP EPS of -$0.34

Aug 09

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:OMIC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	23	-89	N/A	N/A	2
12/31/2025	11	-87	N/A	N/A	2
12/31/2024	2	-89	N/A	N/A	2
3/31/2024	2	-96	-80	-79	N/A
12/31/2023	3	-95	-75	-74	N/A
9/30/2023	3	-93	-77	-75	N/A
6/30/2023	2	-94	-83	-80	N/A
3/31/2023	2	-93	-90	-85	N/A
12/31/2022	1	-91	-93	-87	N/A
9/30/2022	N/A	-90	-89	-83	N/A
6/30/2022	N/A	-83	-79	-72	N/A
3/31/2022	N/A	-97	-68	-62	N/A
12/31/2021	N/A	-99	-57	-52	N/A
9/30/2021	N/A	-87	-46	-43	N/A
6/30/2021	N/A	-77	-41	-39	N/A
3/31/2021	N/A	-47	-31	-29	N/A
12/31/2020	N/A	-28	-26	-25	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: OMIC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: OMIC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: OMIC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: OMICDie Einnahmen des Unternehmens (79.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: OMICDie Einnahmen des Unternehmens (79.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von OMIC in 3 Jahren voraussichtlich hoch sein wird

Singular Genomics Systems Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Singular Genomics Systems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2023

Singular Genomics Systems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2023

Consensus revenue estimates decrease by 44%, EPS upgraded

Consensus revenue estimates decrease by 40%

Price target decreased by 24% to US$0.95

Price target decreased by 36% to US$1.25

Recent updates

Singular Genomics Systems, Inc. to Report Q1, 2024 Results on May 14, 2024

Singular Genomics Systems, Inc., Annual General Meeting, May 29, 2024

Singular Genomics Systems, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Singular Genomics Unveils G4X Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis

Singular Genomics Systems, Inc. Showcases New G4X™ Spatial Sequencer at AGBT and Announces Significant Advances in Throughput, Quality, and Usability for G4 Sequencing Platform

Singular Genomics Systems to Transfer the Listing of Common Stock from Nasdaq Global Select Market to Nasdaq Capital Market

Singular Genomics Systems to Transfer the Listing of Common Stock from Nasdaq Global Select Market to Nasdaq Capital Market

Singular Genomics Systems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2023

Singular Genomics Systems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2023

Consensus revenue estimates decrease by 44%, EPS upgraded

New minor risk - Share price stability

Fluent BioSciences Inc. Announces A Partnership with Singular Genomics

Singular Genomics Systems, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Consensus revenue estimates decrease by 40%

New minor risk - Shareholder dilution

Price target decreased by 24% to US$0.95

New major risk - Revenue and earnings growth

Singular Genomics Appoints Marcia Eisenberg, Ph.D., to Board of Directors

Singular Genomics Systems, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Singular Genomics Systems Receives Non-Compliance Notice from Nasdaq

Price target decreased by 36% to US$1.25

Founder recently bought US$139k worth of stock

Consensus revenue estimates decrease by 27%, EPS upgraded

Consensus revenue estimates decrease by 10%, EPS upgraded

Singular Genomics Systems, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Singular Genomics Systems, Inc. Launches Max Read Kits for Single Cell Sequencing on the G4 At AGBT

Founder recently bought US$100k worth of stock

Price target decreased to US$2.83

High number of new and inexperienced directors

Singular Genomics Systems, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Consensus forecasts updated

Singular Genomics cut to Neutral at UBS on delays for sequencer shipments

Consensus forecasts updated

Singular Genomics Systems GAAP EPS of -$0.34

Singular Genomics Systems, Inc. Announces Management Appointments

Singular Genomics Systems, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Singular Genomics Systems, Inc.(NasdaqGS:OMIC) dropped from Russell 2000 Growth Index

High number of new and inexperienced directors

Lead Independent Director recently bought US$89k worth of stock

Consensus revenue estimates fall by 18%

Singular Genomics Systems, Inc. Announces the Formation of Scientific Advisory Board

Singular Genomics Systems, Inc. Announces Management Changes

Singular Genomics Systems, Inc., Annual General Meeting, May 26, 2022

Consensus forecasts updated

Singular Genomics Systems, Inc. to Report Q4, 2021 Results on Mar 02, 2022

Singular Genomics Launches the G4 Sequencing Platform

Founder exercised options to buy US$25m worth of stock.

Singular Genomics Systems, Inc. has completed an IPO in the amount of $224.4 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken